Romlusevimab
Romlusevimab (BRII-198) is a neutralizing recombinant human IgG1 monoclonal antibody against the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1][2].
Product Specifications
CAS Number
[2509447-08-7]
Product Name Alternative
BRII-198
UNSPSC
12352203
Target
SARS-CoV
Type
Inhibitory Antibodies
Related Pathways
Anti-infection
Applications
COVID-19-anti-virus
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/romlusevimab.html
Purity
95.00
Solubility
H2O
Smiles
[Romlusevimab]
Molecular Weight
(145.126 kDa)
References & Citations
[1]Hoy SM. Amubarvimab/Romlusevimab: First Approval. Drugs. 2022 Aug;82 (12) :1327-1331.|[2]Ji Y, et al. Preclinical characterization of amubarvimab and romlusevimab, a pair of non-competing neutralizing monoclonal antibody cocktail, against SARS-CoV-2. Front Immunol. 2022 Sep 14;13:980435.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-P99889/Romlusevimab-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-P99889/Romlusevimab-SDS-MedChemExpress.pdf
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 3
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
RC228481L3V 200 µL
eNOS (NOS3) (NM_001160109) Human Tagged ORF Clone Lentiviral Particle
Ask
View Details